| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2002;33:2827.)
© 2002 American Heart Association, Inc.
Original Contributions |
From the Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy (L.P., M.S., G.P., D.I.); Department of Neurology, Karl-Franzens University of Graz, Graz, Austria (R.S.); and MR-MS Centre, VU Medical Centre, Amsterdam, the Netherlands (F.B.).
Correspondence to Leonardo Pantoni, MD, PhD, Department of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 85, 50134 Firenze, Italy. E-mail pantoni{at}neuro.unifi.it
| Abstract |
|---|
|
|
|---|
Methods Two trained raters evaluated 80 pairs of CT and MRI scans using 2 CT and 4 MRI rating scales for white matter changes. Correlations among the scales were evaluated and regression lines were constructed with each of the CT and MRI scale scores as variables.
Results A high correlation was observed in all the paired comparisons of the 6 scales (Spearmans
ranging from 0.85 to 0.96, P<0.0001). Using regression analysis, we determined numeric parameters to transform the score of 1 scale to the corresponding score for each of the remaining scales and relative confidence intervals. The predictive values of these conversions expressed as R2 ranged from 0.75 to 0.92.
Conclusions The present findings support the view that a good correlation exists among the considered visual rating scales for white matter changes. With the limitation that conversion parameters are calculated by applying a linear regression to partly nonlinear scales, their use allows comparison of the results of previous studies that used different scales and to pool data from past and ongoing clinical trials.
Key Words: leukoaraiosis magnetic resonance imaging tomography, x-ray computed white matter
| Introduction |
|---|
|
|
|---|
The clinical significance of WMCs is still incompletely elucidated.6 For example, the contribution of WMCs to cognitive impairment is still a matter of debate.7 In addition, the pathogenesis of WMCs is under investigation. Today, the most widely accepted opinion is that WMCs represent the radiological appearance of a vascular process linked mainly with cerebral small-vessel changes.8,9 Although the association between WMCs and aging has been consistently shown across different studies,6 conflicting conclusions have been reached as far as other risk factors and clinical correlates are concerned.
A number of causes have been hypothesized to play a role in the contradictory results achieved so far by studies evaluating the frequency, clinical significance, and risk factors of WMCs. Among these causes are (1) differences in subject settings (eg, hospital series versus population cohorts), (2) heterogeneity of patients under evaluation in terms of age and prevalence of risk factors and diseases, and (3) differences in the definition criteria of risk factors. Technical matters could be another possible cause of inconsistency; in fact, WMCs detected by CT or MRI are not exactly exchangeable because MRI is far more sensitive than CT in detecting WMCs.10,11 Moreover, among MRI studies, discordances may derive from the use of different pulse sequences and different magnetic field strengths.
It has also been argued that the use of different WMC rating methods may lead to inconsistent conclusions.12 A method to make uniform the different visual rating scales would be useful for assessing the factual differences across studies and for conducting meta-analyses of data on the association between WMCs and clinical factors. The aims of our study were to assess the correlation of 6 visual rating scales for WMCs (2 CT and 4 MRI based) chosen among the most widely used and to determine numeric parameters that could allow the conversion of different scale scores and consequently the comparison of the results of different studies.
| Materials and Methods |
|---|
|
|
|---|
To evaluate the feasibility of the application of each of the 7 scales on a large series of scans and to become familiar with their use, 2 investigators (L.P., M.S.) with expertise in WMC visual rating scored a first group of 30 pairs of CT and MRI scans. After this trial, we decided not to use the Rezek et al scale for this study because its application resulted to be very time-consuming. Moreover, because basal ganglia and infratentorial lesions were not scored in the remaining 5 scales, we decided to use a modification of the Scheltens et al scale that, unlike the original, did not include scoring of lesions in these 2 locations (see Appendix 1).
For the scope of our study, we selected 80 scans of subjects >60 years of age who underwent both a CT and an MRI study at a maximum of 3 weeks apart. This time interval was chosen to minimize the likelihood of major brain changes between the 2 scan examinations. In addition, no cerebrovascular event was to occur in the interval between the CT and the MRI study. Scans showing large cortical or border-zone infarcts were excluded because these lesions could influence the evaluation of WMCs. Because the aim of the study was to evaluate images, except for the above-mentioned ones, no other clinical criteria for the inclusion of the scans in the study were required. Scans were obtained through a search in the archives of our department and progressive evaluation of subjects admitted as inpatients or outpatients to our department. Attention was paid to include scans with different degrees of WMCs to minimize ceiling or floor effects on scoring. Most of the evaluated scans belonged to patients with cognitive disorders, gait impairment, or vascular risk factors, particularly hypertension.
The same 2 observers who performed the training trial did all the scan ratings. The 6 scales were applied in succession by the 2 raters together, and consensus on each scan rating score was reached. Because MRI is known to be more sensitive than CT in detecting WMCs, CT scans were always evaluated before MRI scans to avoid rating bias. Considering MRI, fluid-attenuated inversion recovery sequences were chosen for the rating when available. In the remaining cases, T2-weighted and/or proton density images were used. All CT scans were performed on a Somatom Plus-4 or Somatom CR machine; 60 MRI studies were acquired on a Philips Gyroscan T5-NT (0.5 T), and the remaining 20 were acquired on a Philips Gyroscan ACS-NT (1.5 T).
Statistical Analysis
Correlations between each couple of rating scales were assessed. For scales scoring periventricular and deep WMCs separately (those of Fazekas et al, Ylikoski et al, and Scheltens et al), we summed the 2 subscores to obtain a total score to be compared with that obtained on the remaining scales (those of Blennow et al, van Swieten et al, and Manolio et al). The level of significance of the relation between the rating scores of each of the 6 considered scales was tested by Spearmans nonparametric correlation.
A linear regression model was applied for each couple of scale scores to transform the score of 1 scale to the score obtained on the second scale of the couple. The predictive value of the model was expressed as R2, ranging from 0 to 1.
| Results |
|---|
|
|
|---|
|
|
Because the linear regression model has a clear limitation in the conversion of nonlinear rating scores such as those of the considered scales, we also present descriptive comparisons of the corresponding rating scores on the 6 scales (Table 2). Because some scales cover a wide range of scores and our observations were limited in number, we pooled some of the scores to have a sufficient number of observations for each comparison.
|
The regressions between the considered pairs of scales are shown in Table 3. The application of 2 parameters to a linear equation allows the conversion of the score obtained on a single scale into the score of another scale. For example, given the score of 2 on the van Swieten et al scale, the converted Blennow et al scale total score is as follows: Y=0.07+0.69x2=1.45. The predictive values of the conversions were generally high, with R2 ranging from 0.75 to 0.92.
|
| Discussion |
|---|
|
|
|---|
The results of our study may have application not only in the evaluation and pooling of already acquired data but also in future investigations, particularly those conducted on a large scale that may use MRI and CT indiscriminately, according to local expertise and available facilities. In fact, although CT is widely recognized to be less sensitive to WMCs than MRI, it is still the most easily accessible neuroimaging procedure in many centers. However, we should point out that finding a correlation between different rating scales does not prove the validity of the scales themselves. Because the main goal of our study was to evaluate the comparability of different scales, we did not make correlation with clinical findings, nor did we assess the validity of the visual rating scales compared with a quantitative measure of WMC load. Therefore, no definite conclusion can be derived in relation to the influence of different visual rating scales on the assessment of clinical correlates of WMCs and on the validity of the scales in respect to the pathological extension of WMCs.
Possible shortcomings of our study need to be taken into account. One major limitation of visual rating scale for WMCs is the interrater variability. In our study, we decided to overcome this drawback by scoring scans by consensus to minimize the effect of disagreement. Moreover, the scales were chosen among those with the highest reported interrater agreement and provided the best instructions and illustrative examples.13 Future studies aiming at applying this study procedure to other scales should take this aspect into consideration either by pretrial assessment of the interrater agreement or by assessment of scans by consensus.
Another caution is that the conclusions of our study can be applied only to the scales that we took into consideration. All the rating scales compared in this study have a similar approach to WMCs; some are even very close to each other. The extension of the calculation of conversion parameters to other scales requires previous demonstration of a good correlation among scale scores. From this point of view, our procedure may serve as an example. A third limitation concerns the predictive values of our conversion parameters. R2 ranged between 0.75 and 0.92, meaning that in the worst case, application of the linear equation to transform the score of a scale into another reaches incorrect conclusions in one fourth of the conversions. During the study, we did not observe an improvement in the R2 values because the number of the observations increased once the first 50 pairs of scans were rated. This would mean that the predictive values depend on intrinsic characteristics of the model rather than on the number of scans. On the other hand, predictive values such as those observed in our study can be considered acceptable, especially when considering the high correlations among scales. Finally, because the scale scores were not linear, the regression analysis represents an obvious simplification and thus presents limitations. The descriptive analyses we reported with the equivalent scores on different scales represent an attempt to solve this issue. However, given that some of the scales have very wide score ranges, only with a much larger number of observations for each score could a conclusion with statistical significance be reached.
From the results of this study, we conclude that a very good correlation is found among the considered scales. Further studies are needed to evaluate whether this conclusion applies to other rating scales for WMCs and to assess whether the correlation with clinical findings is influenced by the application of these scales. Conversion factors derived from our study might be applied for pooling data from past studies on age-related WMCs. Moreover, the use of these conversion factors may prove useful in the identification of subgroups of patients (eg, those with small-vessel disease-related WMCs) in ongoing clinical trials testing new drugs for vascular dementia that used CT or MRI.
| Footnotes |
|---|
| Appendix 1 |
|---|
|
|
|---|
Blennow et al (Minimum, 0; Maximum, 3)
Extension and severity of CT WMCs are rated. The final score is the mean value between the extension and severity scores.
Extent of WMCs
Scores are as follows: 0=no decrease in the attenuation of white matter; 1=decreased attenuation of white matter at the margins at the frontal and occipital horns of the lateral ventricles; 2=decreased attenuation of white matter around the frontal and occipital horns of the lateral ventricles with some extension toward the centrum semiovale; and 3=decreased attenuation of white matter extending around the whole lateral ventricles and coalescing in the centrum semiovale.
Severity of WMCs
Scores are as follows: 0=none, 1=mild, 2=moderate, and 3=marked decrease in the attenuation of white matter.
Fazekas et al (Total Score Minimum, 0; Maximum, 6)
Periventricular and deep WMCs are rated separately. A total score is obtainable by summing the 2 partial scores.
Periventricular Hyperintensities
Scores are as follows: 0=absence, 1="caps" or pencil-thin lining, 2=smooth "halo," and 3= irregular periventricular hyperintensities extending into the deep white matter.
Deep White Matter Hyperintense Signals
Scores are as follows: 0=absence, 1=punctuate foci, 2=beginning confluence of foci, and 3=large confluent areas.
Modified Scheltens et al (Minimum, 0; Maximum, 30)
Periventricular Hyperintensities (Minimum, 0; Maximum 6)
Scoring is as follows: caps, occipital 0/1/2 and frontal 0/1/2; bands, lateral ventricles 0/1/2 (0=absent, 1=
5 mm, 2=
6 mm and
10 mm).
White Matter Hyperintensities (Minimum, 0; Maximum, 24)
Scoring is as follows: frontal 0/1/2/3/4/5/6, parietal 0/1/2/3/4/5/6, occipital 0/1/2/3/4/5/6, temporal 0/1/2/3/4/5/6 (0=no abnormalities, 1=
3 mm, n
5; 2=
3 mm, n
6; 3=4 to 10 mm, n
5; 4=4 to 10 mm, n
6; 5=
11 mm, n
1; 6=confluent).
Ylikoski et al (Total Score Minimum, 0; Maximum 48)
WMCs located at 4 locations (frontal horns, body of the ventricles, trigones, and occipital horns) are rated separately on each hemisphere.
Periventricular Leukoaraiosis (Minimum, 0; Maximum, 24)
Scoring is as follows: 0=no hyperintensity; 1=punctuate, small foci (mild); 2=cap, pencil-thin lining (moderate); and 3=nodular band, extending hyperintensity (severe).
Centrum Semiovale Leukoaraiosis, Including Watershed Areas (Minimum, 0; Maximum, 24)
Scoring is as follows: 0=no hyperintensity; 1=punctuate, small foci (mild); 2=beginning confluent (moderate); and 3=large confluent areas (severe). Total leukoaraiosis score is periventricular leukoaraiosis score plus centrum semiovale leukoaraiosis score equal to 0 to 48.
Manolio et al (Minimum, 0; Maximum, 9)
The total volume of white matter lesions is evaluated with template images and text descriptions. Periventricular and subcortical regions are not rated separately. A text description includes 9 grades: 0=no white matter signal abnormalities; 1=discontinuous periventricular rim or minimal "dots" of subcortical white matter; 2=thin, continuous periventricular rim or few patches of subcortical white matter lesions; 3=thicker continuous periventricular rim with scattered patches of subcortical white matter lesions; 4=thicker shaggier periventricular rim and mild subcortical white matter lesions and may have minimal confluent periventricular lesions; 5=mild, periventricular confluence surrounding frontal and occipital horns; 6=moderate periventricular confluence surrounding frontal and occipital horns; 7=periventricular confluence with moderate involvement of centrum semiovale; 8=periventricular confluence involving most of centrum semiovale; and 9=all white matter involved.
| Appendix 2 |
|---|
|
|
|---|
Received April 1, 2002; revision received June 7, 2002; accepted July 4, 2002.
| References |
|---|
|
|
|---|
2. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Huchinson RG, Tyroler A. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. Stroke. 1996; 27: 22622270.
3. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, OLeary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke. 1996; 27: 12741282.
4. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian Stroke Prevention Study. J Neurol Sci. 1997; 152: 1521.[CrossRef][Medline] [Order article via Infotrieve]
5. Hachinski VC, Potter P, Merskey H, Leuko-araiosis. Arch Neurol. 1987; 44: 2123.
6. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswangers report: a review. Stroke. 1995; 26: 12931301.
7. Inzitari D, Romanelli M, Pantoni L. Leukoaraiosis and cognitive impairment. In: OBrien J, Ames D, Burns A, eds. Dementia. 2nd ed. London, UK: Edward Arnold Publishers; 2000: 635653.
8. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997; 28: 652659.
9. Pantoni L, Leys D, Fazekas F, Longstreth WT Jr, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V. Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S49S54.[CrossRef][Medline] [Order article via Infotrieve]
10. Johnson KA, Davis KR, Buonanno FS, Brady TJ, Rosen TJ, Growdon JH. Comparison of magnetic resonance and roentgen ray computed tomography in dementia. Arch Neurol. 1987; 44: 10751080.
11. Lopez OL, Becker JT, Jungreis CA, Rezek D, Estol C, Boller F, DeKosky ST. Computed tomography- but not magnetic resonance imaging-identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimers disease. Arch Neurol. 1995; 52: 659664.
12. Mäntylä R, Erkinjuntti T, Salonen O, Aronen HJ, Peltonen T, Pohjasvaara T, Standertskjold-Nordenstam C-G. Variable agreement between visual rating scales for white matter hyperintensities on MRI. Stroke. 1997; 28: 16141623.
13. Scheltens Ph, Erkinjuntti T, Leys D, Wahlund L-O, Inzitari D, del Ser T, Pasquier F, Barkhof F, Mäntylä R, Bowler J, Wallin A, Ghika J, Fazekas F, Pantoni L. White matter changes on CT and MRI: an overview of visual rating scales. Eur Neurol. 1998; 39: 8089.[CrossRef][Medline] [Order article via Infotrieve]
14. Rezek DL, Morris JC, Fulling KH, Gado MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology. 1987; 37: 13651368.
15. Van Swieten JC, Hijdra A, Koudstaal PJ, Van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry. 1990; 53: 10801083.
16. Blennow K, Wallin A, Uhlemann C, Gottfries GC. White matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand. 1991; 83: 187193.[Medline] [Order article via Infotrieve]
17. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimers dementia and normal aging. AJNR Am J Neuroradiol. 1987; 8: 421426.
18. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJP, Vermersch P, Steinling M, Valk J. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993; 114: 712.[CrossRef][Medline] [Order article via Infotrieve]
19. Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol. 1993; 50: 818824.
20. Manolio TA, Kronmal RA, Burke GL, Poirier V, OLeary DH, Gardin JM, Fried L, Steinberg EP, Bryan RN, for the Cardiovascular Health Study Collaborative Research Group. Magnetic resonance abnormalities and cardiovascular disease in older adults: the ARIC study. Stroke. 1994; 25: 318327.[Abstract]
21. Leys D, Soetaert G, Petit H, Fauquette A, Pruvo JP, Steinling M. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimers disease and normal aging. Arch Neurol. 1990; 47: 524527.
22. Kozachuk WE, DeCarli C, Schapiro MB, Wagner EE, Rapoport SI, Horwitz B. White matter hyperintensities in dementia of Alzheimers type and in healthy subjects without cerebrovascular risk factors: a magnetic resonance imaging study. Arch Neurol. 1990; 47: 13061310.
23. Kittner B. Clinical trials of propentofylline in vascular dementia: European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S166S171.[Medline] [Order article via Infotrieve]
24. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000; 175: 124134.[CrossRef][Medline] [Order article via Infotrieve]
25. Rossi R, Inzitari D, Pantoni L, del Ser T, Erkinjuntti T, Wallin A, Bianchi C, Badenas JM, Beneke M. Nimodipine in subcortical vascular dementia trial. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S159S165.[Medline] [Order article via Infotrieve]
26. Scheltens P, Kittner B. Preliminary results from an MRI/CT-based database for vascular dementia and Alzheimers disease. Ann N Y Acad Sci. 2000; 903: 542546.[CrossRef][Medline] [Order article via Infotrieve]
27. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998; 29: 11771181.
28. Fazekas F, Barkhof F, Wahlund L-O, Pantoni L, Erkinjuntti T, Scheltens P, Schmidt R. CT and MRI rating of white-matter lesions. Cerebrovasc Dis. 2002; 13 (suppl 2): 3136.[CrossRef]
29. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001; 32: 13181322.
This article has been cited by other articles:
![]() |
A. Jaillard, B. Naegele, S. Trabucco-Miguel, J. F. LeBas, and M. Hommel Hidden Dysfunctioning in Subacute Stroke * Supplemental Appendix Stroke, July 1, 2009; 40(7): 2473 - 2479. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Levy-Cooperman, J. Ramirez, N. J. Lobaugh, and S. E. Black Misclassified Tissue Volumes in Alzheimer Disease Patients With White Matter Hyperintensities: Importance of Lesion Segmentation Procedures for Volumetric Analysis Stroke, April 1, 2008; 39(4): 1134 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L.C. Vogels, W. M. van der Flier, B. van Harten, A. A. Gouw, P. Scheltens, J. M. Schroeder-Tanka, and H. C. Weinstein Brain magnetic resonance imaging abnormalities in patients with heart failure Eur J Heart Fail, October 1, 2007; 9(10): 1003 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schmidt, K. Petrovic, S. Ropele, C. Enzinger, and F. Fazekas Progression of Leukoaraiosis and Cognition Stroke, September 1, 2007; 38(9): 2619 - 2625. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Nave, S. Foresti, A. Pratesi, A. Ginestroni, M. Inzitari, E. Salvadori, M. Giannelli, S. Diciotti, D. Inzitari, and M. Mascalchi Whole-Brain Histogram and Voxel-Based Analyses of Diffusion Tensor Imaging in Patients with Leukoaraiosis: Correlation with Motor and Cognitive Impairment AJNR Am. J. Neuroradiol., August 1, 2007; 28(7): 1313 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hachinski, C. Iadecola, R. C. Petersen, M. M. Breteler, D. L. Nyenhuis, S. E. Black, W. J. Powers, C. DeCarli, J. G. Merino, R. N. Kalaria, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Stroke, September 1, 2006; 37(9): 2220 - 2241. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C.W. van Straaten, F. Fazekas, E. Rostrup, P. Scheltens, R. Schmidt, L. Pantoni, D. Inzitari, G. Waldemar, T. Erkinjuntti, R. Mantyla, et al. Impact of White Matter Hyperintensities Scoring Method on Correlations With Clinical Data: The LADIS Study Stroke, March 1, 2006; 37(3): 836 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Murray, R. T. Staff, S. D. Shenkin, I. J. Deary, J. M. Starr, and L. J. Whalley Brain White Matter Hyperintensities: Relative Importance of Vascular Risk Factors in Nondemented Elderly People Radiology, October 1, 2005; 237(1): 251 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dufouil, J. Chalmers, O. Coskun, V. Besancon, M.-G. Bousser, P. Guillon, S. MacMahon, B. Mazoyer, B. Neal, M. Woodward, et al. Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy Circulation, September 13, 2005; 112(11): 1644 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jeerakathil, P. A. Wolf, A. Beiser, J. Massaro, S. Seshadri, R. B. D'Agostino, and C. DeCarli Stroke Risk Profile Predicts White Matter Hyperintensity Volume: The Framingham Study Stroke, August 1, 2004; 35(8): 1857 - 1861. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |